MedTrace Logo

Canadian Real-World Outcomes of Omnipod Initiation in People With T1D

NCT04226378 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 286

Last updated 2020-02-21

No results posted yet for this study

Summary

The current study aims to assess clinical outcomes in adults with type 1 diabetes (T1D) who have switched from traditional multiple daily injection (MDI) therapy to continuous subcutaneous insulin infusion (CSII) therapy with the Omnipod insulin system.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DEVICE

Omnipod

Switch from MDI therapy to an Omnipod as part of usual clinical practice. An Omnipod is a patch pump that consists of a handheld controller and a disposable pod that delivers insulin.

OTHER

MDI

Continued use of MDI therapy (traditional basal/bolus insulin regimen).

Sponsors & Collaborators

  • Insulet Corporation

    collaborator INDUSTRY

  • LMC Diabetes & Endocrinology Ltd.

    lead OTHER

Principal Investigators

  • Ronnie Aronson · LMC Healthcare

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-20
Primary Completion
2020-02-09
Completion
2020-02-09
FDA Device
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04226378 on ClinicalTrials.gov